Aytu BioPharma, Inc.
corporate_fare Company Profile
Aytu BioPharma, Inc. (NASDAQ:AYTU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for AYTU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AYTU spans 8-K, 10-K, 10-Q.
Recent high-impact activity:
- Aytu Tops Q1 Estimates as EXXUA Prescriptions Jump 33% Sequentially
- Aytu Posts Q1 FY2027 Revenue of $14.8M, Skips Earnings Call Ahead of $2.70/Share Rosemont Deal
- Rosemont to Buy Aytu BioPharma for $2.70 a Share in All-Cash Tender Offer
- Aytu FY2026 10-K: EXXUA Launch Drives $57.6M Revenue, Net Loss Narrows to $14.3M
- Aytu BioPharma Q4 Revenue Rises 6.4% as EXXUA Launch Gains Traction
Financial Snapshot
Short Interest & Short Volume
11.65 days to coverFINRA reported short interest of 301,698 shares in AYTU as of the October 30, 2026 settlement, a 8.3% decrease from the prior period — about 11.7 days to cover at its recent average daily volume. On November 20, 2026, 42.0% of AYTU volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.